"This really is an individual decision for each woman," said genetic counselor, Cheryl Knight, MS, LCGC with Doylestown Health's Cancer Institute. Cheryl is the Cancer Risk Evaluation Program Coordinator. "Each woman needs to plot a course based on her own personal health history and her reproductive decisions. Current guidelines suggest a woman who has a BRCA1 mutation make a decision by age 40. It should be a process. Each woman needs to consult with her doctor and consider all the options."
FORCE, Facing Our Risk of Cancer Empowered, holds support groups for women with the BRCA1 in the Philadelphia area. FORCE is also holding their international conference in May in Philadelphia for people and families affected by hereditary cancer or BRCA mutation.
About Doylestown Health's Cancer InstituteAccredited by the American College of Surgeons Commission on Cancer, Doylestown Health's Cancer Institute offers patients the quality care they expect from a leader in cancer diagnosis and treatment— close to home. Comprehensive services include oncology-certified patient navigators, a state-of-the art infusion suite, Penn Radiation Oncology on site, and access to cutting-edge therapies and innovative clinical trials through the Penn Cancer Network.
Visit Doylestown Health's Cancer Institute or connect with us on Facebook or Twitter.